Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)

Michael Benatar, Joanne Wuu, Peter M. Andersen, Robert C. Bucelli, Jinsy A. Andrews, Markus Otto, Nita A. Farahany, Elizabeth A. Harrington, Weiping Chen, Adele A. Mitchell, Toby Ferguson, Sheena Chew, Liz Gedney, Sue Oakley, Jeong Heo, Sowmya Chary, Laura Fanning, Danielle Graham, Peng Sun, Yingying LiuJanice Wong, Stephanie Fradette

Research output: Contribution to journal › Comment/debate

5 Scopus citations

Fingerprint

Dive into the research topics of 'Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study (Neurotherapeutics, (2022), 19, 4, (1248-1258), 10.1007/s13311-022-01237-4)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science